Skip to main content
SpringerLink
Log in

Antiangiogenesis, Anti-VEGF(R) and Outlook

  • Chapter
Targeted Therapies in Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 176))

Abstract

Tumor angiogenesis and antiangiogenesis has moved from an exotic research topic into clinical practice defining a new and promising avenue of targeted cancer therapy. Starting with a historical perspective on tumor angiogenesis, this review provides the basic concepts and classification of angiogenesis inhibition. Focusing primarily on vascular endothelial growth factor (VEGF), the biological activity and regulation of the gene expression of VEGF, its isoforms, and the receptors are summarized. Furthermore, naturally occurring modulators are listed, an overview on angiogenesis inhibitors in clinical trails is provided, and finally a brief outlook is given on this fascinating and rapidly evolving field of oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Achen MG, Williams RA, Minekus MP, Thornton GE, Stenvers K, Rogers PA, Lederman F, Roufail S, Stacker SA (2001) Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 193:147–154

    Article  PubMed  CAS  Google Scholar 

  • Bagri A, Tessier-Lavigne M (2002) Neuropilins as Semaphorin receptors: in vivo functions in neuronal cell migration and axon guidance. Adv Exp Med Biol 515:13–31

    PubMed  CAS  Google Scholar 

  • Baldwin ME, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, Karkkainen MJ, Alitalo K, Stacker SA, Achen MG (2001) The specificity of receptor binding by vascular endothelial growth factord is different in mouse and man. J Biol Chem 1276:19166–19171

    Article  Google Scholar 

  • Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159–165

    PubMed  CAS  Google Scholar 

  • Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 27390:404–407

    Article  CAS  Google Scholar 

  • Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575–583

    Article  PubMed  CAS  Google Scholar 

  • Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, Carmeliet P (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8:702–710

    PubMed  CAS  Google Scholar 

  • Ellis LM (2004) Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol 31:3–9

    Article  PubMed  CAS  Google Scholar 

  • Fayette J, Soria JC, Armand JP (2005) Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 41:1109–1116

    Article  PubMed  CAS  Google Scholar 

  • Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611

    Article  PubMed  CAS  Google Scholar 

  • Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 15161:851–858

    Article  Google Scholar 

  • Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

    Article  PubMed  CAS  Google Scholar 

  • Folkman J, Merler E, Abernathy C, Williams G (1971a) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1133:275–288

    Article  Google Scholar 

  • Folkman J (1971b) Tumor angiogenesis: therapeutic implications. N Engl J Med 18285:1182–1186

    Google Scholar 

  • Folkman J, Klagsbrun M (1987) Vascular physiology. A family of angiogenic peptides. Nature 329:671–672

    Article  PubMed  CAS  Google Scholar 

  • Gerber HP, Dixit V, Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 22273:13313–13316

    Article  Google Scholar 

  • Gupta K, Zhang J (2005) Angiogenesis: a curse or cure? Postgrad Med J 81:236–242

    Article  PubMed  CAS  Google Scholar 

  • He Y, Karpanen T, Alitalo K (2004) Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 41654:3–12

    Google Scholar 

  • Huang K, Andersson C, Roomans GM, Ito N, Claesson-Welsh L (2001) Signaling properties of VEGF receptor-1 and-2 homo-and heterodimers. Int J Biochem Cell Biol 33:315–324

    Article  PubMed  CAS  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 3350:2335–2342

    Article  Google Scholar 

  • Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K (2004) Vascular endothelial growth factor C is required for sprouting of first lymphatic vessels from embryonic veins. Nat Immunol 5:74–80

    Article  PubMed  CAS  Google Scholar 

  • Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–739

    Article  PubMed  CAS  Google Scholar 

  • Klagsbrun M, Takashima S, Mamluk R (2002) The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 515:33–48

    PubMed  CAS  Google Scholar 

  • Ku DD, Zaleski JK, Liu S, Brock TA (1993) Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 265:H586–H592

    PubMed  CAS  Google Scholar 

  • Matsumoto T, Claesson-Welsh L (2001) VEGF receptor signal transduction. Sci STKE 2001 Dec 11: RE21

    Google Scholar 

  • Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 52:43–47

    Article  PubMed  CAS  Google Scholar 

  • Muhsin M, Graham J, Kirkpatrick P (2004) Bevacizumab. Nat Rev Drug Discov 3:995–996

    Article  PubMed  CAS  Google Scholar 

  • Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 1565:3967–3979

    Article  Google Scholar 

  • O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 2488:277–285

    Article  Google Scholar 

  • Park JE, Chen HH, Winer J, Houck KA, Ferrara N (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 14269:25646–25654

    Google Scholar 

  • Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF (2003) A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9:1323–1332

    PubMed  CAS  Google Scholar 

  • Rundhaug JE (2005) Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9:267–285

    Article  PubMed  CAS  Google Scholar 

  • Saharinen P, Tammela T, Karkkainen MJ, Alitalo K (2004) Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25:387–395

    Article  PubMed  CAS  Google Scholar 

  • Semenza G (2002) Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64:993–998

    Article  PubMed  CAS  Google Scholar 

  • Serini G, Valdembri D, Bussolino F (2005) Integrins and angiogenesis: a sticky business. Exp Cell Res 312:651–658

    Article  PubMed  CAS  Google Scholar 

  • Tammela T, Enholm B, Alitalo K, Paavonen K (2005) The biology of vascular endothelial growth factors. Cardiovasc Res 1565:550–563

    Article  CAS  Google Scholar 

  • Tandle A, Blazer DG 3rd, Libutti SK (2004) Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2:20

    Article  CAS  Google Scholar 

  • Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, Ross J, Jin H (1996) Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27:838–844

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie Rudolf-Virchow-Haus, Humboldt-Universität Berlin, Charité Campus Mitte, 10117, Berlin, Germany

    Iver Petersen MD

Authors
  1. Iver Petersen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Pathologie, Charité Humboldt-Universität zu Berlin, Schumanstr. 20-21, 10117, Berlin, Germany

    Manfred Dietel

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Petersen, I. (2007). Antiangiogenesis, Anti-VEGF(R) and Outlook. In: Dietel, M. (eds) Targeted Therapies in Cancer. Recent Results in Cancer Research, vol 176. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-46091-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-46091-6_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-46090-9

  • Online ISBN: 978-3-540-46091-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation